We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Acorda Fighting Six Generic Challenges to Ampyra

Acorda Fighting Six Generic Challenges to Ampyra

July 24, 2014

Brand manufacturer Acorda is fending off at least six different generic challenges filed in the last few weeks to its multiple sclerosis drug Ampyra.

Acorda confirmed the first Paragraph IV ANDA against Ampyra (dalfampridine) in a June 26 statement that vowed to defend the company’s intellectual property rights against all challenges.

As of Friday, Acorda had filed separate infringement lawsuits in the U.S. District Court for the District of Delaware against the following ANDA filers: Actavis on June 24, Aurobindo Pharma on June 26, Roxane Laboratories on July 1, Alkem Laboratories on July 2, Accord Healthcare on July 7, and Mylan on July 9.

Most of the ANDA filers are challenging all five of Ampyra’s patents: the ’938, ’826, ’437, ’703 and ’685, based on court filings.

The last of Ampyra’s patents expires in 2027, according to the Orange Book. An Acorda spokesman said the FDA was able to start accepting challenges to the patents in January. “The timing of the ANDA filers is impacted by a number of factors which include the FDA review timelines,” Jeff Macdonald said.

Acorda is joined in the lawsuit by Irish drugmaker Alkermes, which owns the ‘938 patent and has licensed it exclusively to Acorda, according to court filings. Acorda owns the rest of the patents.

Ampyra is the first drug authorized for helping MS patients to improve walking, and has Orphan Drug status that extends until 2017, Acorda has said. The drug also has new chemical entity exclusivity until January 2015, according to the Orange Book.

The drug, which is Acorda’s flagship product, generated net revenues of $72.5 million in the first quarter of this year, according to the firm’s most recent earnings statement. — Bryan Koenig

Originally appeared in Drug Industry Daily, the pharmaceutical industry’s number one source for regulatory news and information. Click here for more information.

Pharmaceuticals Commercial Operations

Upcoming Events

  • 13Jul

    FDA Ad and Promo Enforcement Trends: Past, Present and Future

  • 28Jul

    EU-MDR’s Growing Pains: Are You Current with the Latest Developments?

  • 28Jul

    Is Your Product a Drug or Device — and Does It Matter?: A Recent Appeals Court Decision Says It Does

  • 02Aug

    Medical Device Cybersecurity: Understand the Latest Developments

  • 03Aug

    Pharmaceutical Process Validation: Best Practices for Success

  • 10Aug

    Gene & Cell Therapy Regulation: Comparability and Other New Developments

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • FDA Provides Update on GE Healthcare’s Recall of Its Carescape R860 Ventilators

  • Gilead Resubmits NDA for Lenacapavir Following Complete Response Letter

  • FDA Warns Baby Neck Floats Used in Water Therapy Can Cause Death or Injury

  • U.S. Government Inks $3.2 Billion Contract With Pfizer-BioNTech for Vaccine Booster Campaign

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing